COMP <GO>
ADMA vs UNH // ENTERPRISE SCALE & MARKET CAP
ADMA Biologics Inc (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ADMA 8
— UNH 4
▲ ENTERPRISE SCALE & MARKET CAP LEADER: UNH
LAST: $11.41 (-2.89%) • MKT CAP: $2.63B
market-cap
$2.63B
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
market-cap
$368.83B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADMA VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADMA | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.40% | 88.57% | -31.17 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 32.90% | 11.47% | +21.43 | ADMA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.4x | 16.4x | -4.05 | ADMA | /valuation <GO> |
| Free Cash Flow Yield | 1.06% | 6.48% | -5.42 | UNH | /fcf-yield <GO> |
| Operating Margin | 37.50% | 4.82% | +32.68 | ADMA | /operating-margins <GO> |
| Net Profit Margin | 28.80% | 3.14% | +25.66 | ADMA | /net-margins <GO> |
| Revenue Growth (YoY) | 19.60% | 6.46% | +13.14 | ADMA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.98 | 3.12 | +9.86 | ADMA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.9 | 59.2 | +8.70 | ADMA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.0x | 17.7x | -2.74 | ADMA | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.63B | $368.83B | -$366.20B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADMA REV | UNH REV | ADMA GROSS % | UNH GROSS % | ADMA FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $510.2M | $447.57B | 57.4% | 88.7% | $27.8M | $16.07B |
| FY 2024 | $426.5M | $400.28B | 51.5% | 88.3% | $110.4M | $20.70B |
| FY 2023 | $258.2M | $371.62B | — | 89.6% | $8.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADMA // BETA —
UNH // BETA 0.33